Association of Metformin Use and Survival Outcome in Women With Cervical Cancer

• DOI: 10.1097/igc.0000000000001036
• Publication Date: 2017-06-22T11:06:41Z
• Authors: Tsuyoshi Takiuchi; Hiroko Machida; Marianne S. Hom; Sayedamin Mostofi...; Marina Frimer; Laurie L. Brunette; Koji Matsuo
• Keywords: Univariate analysis

Objective Although preclinical studies suggest possible antitumor effects of metformin against cervical cancer, there is currently a lack clinical data examining the association use and survival in women with cancer. The aim this study was to examine cancer who were receiving metformin. Methods This retrospective consecutive cases stages I IV between 2000 2014. Patient demographics, medication use, tumor characteristics, treatment patterns, outcomes correlated use. Results There 70 (8.9%; 95% confidence interval [CI], 6.9–10.9) users 715 nonusers identified for analysis. Median follow-up time 22.6 months. Recurrence/progression disease death due observed 236 163 cases, respectively. Metformin more likely be older, hypertensive, diabetic, dyslipidemic compared (all, P < 0.05). On univariate analysis, had similar progression-free (PFS) (5-year rates; 57.3% vs 61.8%; = 0.82) cancer–specific overall (71.7% 70.7%; 0.86). After adjusting patient demographics not associated PFS (adjusted hazards ratio, 1.11; CI, 0.70–1.74; 0.67) or 0.91; 0.52–1.60; 0.75). Among 478 received whole pelvic radiotherapy, ( 0.93) 0.32). Conclusions In population,